These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20629676)

  • 1. Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
    Colagiovanni A; Rizzi A; Buonomo A; De Pasquale T; Pecora V; Sabato V; Aruanno A; Pascolini L; Nucera E; Schiavino D
    Contact Dermatitis; 2010 Aug; 63(2):107-8. PubMed ID: 20629676
    [No Abstract]   [Full Text] [Related]  

  • 2. Delayed hypersensitivity skin reaction to enoxaparin.
    Méndez J; de la Fuente R; Stolle R; Vega JM; Sanchís ME; Armentia A; Sánchez P; Fernández A
    Allergy; 1996 Nov; 51(11):853-4. PubMed ID: 8947349
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intolerance of fondaparinux in a patient allergic to heparins.
    Hirsch K; Ludwig RJ; Lindhoff-Last E; Kaufmann R; Boehncke WH
    Contact Dermatitis; 2004 Jun; 50(6):383-4. PubMed ID: 15274739
    [No Abstract]   [Full Text] [Related]  

  • 5. Eczema-like plaques to enoxaparin.
    Valdés F; Vidal C; Fernández-Redondo V; Peteiro C; Toribio J
    Allergy; 1998 Jun; 53(6):625-6. PubMed ID: 9689351
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy.
    Utikal J; Peitsch WK; Booken D; Velten F; Dempfle CE; Goerdt S; Bayerl C
    Thromb Haemost; 2005 Oct; 94(4):895-6. PubMed ID: 16270653
    [No Abstract]   [Full Text] [Related]  

  • 7. Immediate type hypersensitivity after injection of nadroparin (Fraxiparin).
    Bekkenk MW; van Zuuren EJ
    Thromb Haemost; 2005 Sep; 94(3):673-4. PubMed ID: 16268488
    [No Abstract]   [Full Text] [Related]  

  • 8. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed hypersensitivity challenged by subcutaneous Bemiparin.
    Moreno Escobosa MC; Moya Quesada MC; Granados SC; Amat López J
    Allergol Immunopathol (Madr); 2011; 39(5):309-10. PubMed ID: 21129837
    [No Abstract]   [Full Text] [Related]  

  • 12. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux.
    Maetzke J; Hinrichs R; Schneider LA; Scharffetter-Kochanek K
    Allergy; 2005 Mar; 60(3):413-5. PubMed ID: 15679737
    [No Abstract]   [Full Text] [Related]  

  • 13. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.
    Lobo B; Finch C; Howard A; Minhas S
    Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
    ; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
    N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergy 'sucks': leeches may also be harmful.
    Kukova G; Gerber PA; Antal AS; Homey B
    Contact Dermatitis; 2010 Feb; 62(2):124-5. PubMed ID: 20136902
    [No Abstract]   [Full Text] [Related]  

  • 17. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy.
    Maetzke J; Hinrichs R; Staib G; Scharffetter-Kochanek K
    Allergy; 2004 Feb; 59(2):237-8. PubMed ID: 14763948
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans.
    Ludwig RJ; Beier C; Lindhoff-Last E; Kaufmann R; Boehncke WH
    Contact Dermatitis; 2003 Sep; 49(3):158-9. PubMed ID: 14678213
    [No Abstract]   [Full Text] [Related]  

  • 19. Delayed hypersensitivity to enoxaparin.
    Cabañas R; Caballero MT; López-Serrano MC; Díaz R; Contreras J; Barranco P; Moreno-Ancillo A
    J Investig Allergol Clin Immunol; 1998; 8(6):383-4. PubMed ID: 10028487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux.
    Koch P
    Contact Dermatitis; 2003 Dec; 49(6):276-80. PubMed ID: 15025697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.